Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2807435 | 0.81 | MAPT (0.37) | POLBMAPTCYP1A2CYP2D6KMT2A | |
| SCHEMBL30605590 | 0.76 | NOTUM (0.43) | MAPTCYP1A2CYP2D6KMT2AMEN1 | |
| SCHEMBL5189998 | 0.76 | NOTUM (0.43) | MAPTCYP1A2CYP2D6KMT2AMEN1 | |
| SCHEMBL6141075 | 0.72 | LMNA (0.37) | POLBKMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL10498362 | 0.70 | MAPT (0.40) | POLBMAPTCYP1A2CYP2D6KMT2A | |
| SCHEMBL16151331 | 0.70 | POLB (0.48) | POLBMAPTCYP1A2KMT2AMEN1 | |
| SCHEMBL893875 | 0.70 | MEN1 (0.44) | POLBKMT2AMEN1ALDH1A1 | |
| SCHEMBL218052 | 0.69 | — | — | |
| Ammonia Solution, Strong SCHEMBL27915759 | 0.69 | ALDH1A1 (0.50) | MAPTKMT2AMEN1ALDH1A1L3MBTL1 | |
| SCHEMBL1123880 | 0.69 | MAPT (0.54) | POLBMAPTCYP1A2CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3555095-B1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2023-04-12 | — | — | EP | disclosed |
| US-10987354-B2 | Inhibitors of influenza virus replication and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2021-04-27 | — | — | US | disclosed |
| US-20200085822-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2020-03-19 | — | — | US | disclosed |
| US-6919347-B2 | Bradykinin B1 receptor antagonists | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2005-07-19 | — | — | US | disclosed |
| US-20030229092-A1 | Antidiabetic agents; antiinflammatory agents; analgesics; antiallergens | PHARMACOPEIA, INC. (US) | 2003-12-11 | — | — | US | disclosed |
| EP-1196411-B1 | BRADYKININ B1 RECEPTOR ANTAGONISTS | PHARMACOPEIA INC (US) | 2003-09-17 | — | — | EP | disclosed |
| EP-1196411-A1 | BRADYKININ B1 RECEPTOR ANTAGONISTS | PHARMACOPEIA, INC. (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2001005783-A1 | BRADYKININ B1 RECEPTOR ANTAGONISTS | PHARMACOPEIA, INC. (US) | 2001-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229092-A1 | Antidiabetic agents; antiinflammatory agents; analgesics; antiallergens | BDKRB1, BDKRB2, HRH2 | POLB 1746/4885MAPT 4096/4885CYP1A2 2595/4885 |
| US-10987354-B2 | Inhibitors of influenza virus replication and uses thereof | ZC3HAV1, MAVS, POLRMT | POLB 35/4885MAPT 3480/4885CYP1A2 2454/4885 |
| US-20200085822-A1 | INHIBITORS OF INFLUENZA VIRUS REPLICATION AND USES THEREOF | ZC3HAV1, MAVS, POLRMT | POLB 35/4885MAPT 3480/4885CYP1A2 2454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.